A Combination Study of CAR-T Therapy in r/r B-NHL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Drug: BTK inhibitorDrug: PD-1 inhibitor
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT05871684
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- Conditions
- Carcinoma, HepatocellularHepatitis B, ChronicHepatitis C, ChronicCirrhosis, LiverNon-Alcoholic Fatty Liver Disease
- Interventions
- Behavioral: Liver cancer surveillance every 6 monthsBehavioral: Liver cancer surveillance every 3 monthsBehavioral: Liver cancer surveillance annually
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20000
- Registration Number
- NCT05870969
- Locations
- 🇨🇳
Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Real World Study of Linperlisib for Lymphoma Treatment
- Conditions
- Focus on the Lymphoma Including B/T-cell Lymphoma
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05863871
- Locations
- 🇨🇳
Tianjin Cancer Hospital/ Tianjin medical university cancer institute & hospital, Tianjin, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Procedure: Hematopoietic Cell Transplantation
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05863845
Risk Evaluation by COronary CTA and Artificial IntelliGence Based fuNctIonal analyZing tEchniques - II
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT05856110
- Locations
- 🇨🇳
First affiliated hospital of Dalian Medical College, Dalian, Liaoning, China
🇨🇳First affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Cangzhou Center Hospital, Cangzhou, Hebei, China
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05852028
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, China
🇨🇳Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, China
Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- Diagnostic Test: 68Ga-FAPI-04 PET
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05845151
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer
- Conditions
- Prostate CancerPSMAp2PSA
- Interventions
- Diagnostic Test: Prostate biopsy
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05822726
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
- Conditions
- Relapsed or Refractory B-cell Lymphoma
- Interventions
- Drug: Relma-cel
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT05806580
- Locations
- 🇨🇳
NO.197， Ruijin Er Road, Shanghai, Shanghai, China
Axi-cel Retreatment in Relapsed/Refractory LBCL
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05800067
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China